15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Royalty Pharma Plc, 6 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $42.00 to $66.00, a moderate spread. The average target of $58.50 sits 2% below the current $59.98. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 5 to 6 over recent months. On the fundamentals, the Street sees consensus EPS building from about $1.13 next quarter toward $5.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy6100%
Hold00%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Royalty Pharma Plc.
As of Jul, 6 of 6 firms rate RPRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
RPRX EPS & revenue forecast
EPS · NEXT QUARTER
$1.13
Range $1.08 – $1.21 · 5 analysts · -4% YoY
Next period, 5 analysts expect Royalty Pharma Plc to earn $1.13 a share (range $1.08 – $1.21), versus $1.17 a year earlier. Full-year consensus is $5.23, growing to $5.59 the year after.
REVENUE · NEXT QUARTER
$866.8M
Range $855.0M – $885.3M · 5 analysts · +6% YoY
Revenue is expected to reach $866.8M (range $855.0M – $885.3M), +6.5% year-over-year. Full-year consensus is $3.5B, rising to $3.7B next year.
Top analysts covering Royalty Pharma Plc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on RPRX.
#1
Geoff Meacham
Citigroup
Buy
$66.00+10.0% to target
Coverage
—
+ Follow
#2
Terence Flynn
Morgan Stanley
Buy
$63.00+5.0% to target
Coverage
—
+ Follow
#3
SS
Steve Scala
TD Cowen
Buy
$65.00+8.4% to target
Coverage
—
+ Follow
#4
AH
Asad Haider
Goldman Sachs
Buy
$59.00-1.6% to target
Coverage
—
+ Follow
#5
CS
Chris Schott
JP Morgan
Buy
$58.00-3.3% to target
Coverage
—
+ Follow
RPRX stock forecast FAQ
What is RPRX's average 12-month price target?+
The 6 analysts with a live target average $58.50 for Royalty Pharma Plc over the next 12 months, ranging from a $66.00 high to a $42.00 low.
Is RPRX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 6 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for RPRX?+
The Street-high target is $66.00 (Citigroup), and the Street-low is $42.00 (Goldman Sachs). The average of all 6 active targets is $58.50.
How many Wall Street analysts cover RPRX?+
6 analysts have an active rating on Royalty Pharma Plc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering RPRX?+
Among analysts who currently cover RPRX, Geoff Meacham of Citigroup has the strongest overall Quantellect track record. Their current call is Buy with a $66.00 target.
What is Royalty Pharma Plc's projected EPS for next quarter?+
The consensus estimate is $1.13 per share (range $1.08 – $1.21) across 5 analysts. Full-year EPS is projected at $5.23, rising to $5.59 the following year.
How much revenue is Royalty Pharma Plc expected to report next quarter?+
Consensus revenue is $866.8M (range $855.0M – $885.3M). Full-year revenue is projected at $3.5B, growing to $3.7B next year.
Have analysts been upgrading or downgrading RPRX lately?+
As of Jul, 6 of 6 firms rate RPRX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their RPRX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
